drugset
drugset / Trial / NCT06570447

Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

NCT06570447 ↗

Phase 2 Recruiting 22 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

An open-label, single-arm, single-center, phase II clinical trial to evaluate the feasibility, efficacy and safety of Glofitamab Combination with chidamide in patients with recurrent/refractory diffuse large B-cell lymphoma.

Timeline

Start
2025-05-15
Primary completion
2026-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Glofitamab Monoclonal antibody 30 mg —
Subject Tucidinostat Small molecule 30 mg Oral

Indications

diffuse large B-cell lymphoma